Based on: Atrial Fibrillation — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 52 candidate interventions for atrial Fibrillation that are either approved medicines or have at least one registered clinical trial, built on 9 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 4 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Catheter Ablation — 3 registered trials · investigational · NCT03388333 NCT01173796
- Rivaroxaban — 2 registered trials · approved medicine · NCT03996772 NCT02273700
- Dabigatran — 2 registered trials · investigational · NCT03996772 NCT01994265
- Oral anticoagulant — 2 registered trials · investigational · NCT04099238 NCT04233515
- Digoxin — 1 registered trial · approved medicine · NCT02391337
- Edoxaban — 1 registered trial · approved medicine · NCT05732506
- Warfarin — 1 registered trial · approved medicine · NCT01994265
- 12-Lead ECG — 1 registered trial · investigational · NCT03492554
- 14 Day ECG Patch (Zio XT Patch, iRhythm Technologies) — 1 registered trial · investigational · NCT03221777
- Ablation — 1 registered trial · investigational · NCT01898221
- Adaptive Servo-Ventilation — 1 registered trial · investigational · NCT00263757
- Adenosine test — 1 registered trial · investigational · NCT02238392
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in atrial Fibrillation and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ADRB1, AGTR1, GJA1, KCNA5, KCNH2, KCNQ1, RYR2, SCN5A, TGFB1.
Which trials are registered?
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation NCT07626411 · Recruiting · Phase PHASE3 · started 2026-08-10
- Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation NCT07424690 · Recruiting · Phase NA · started 2026-10-05
- A Village Doctor-led Telehealth Supported Improvement of Outcomes of AF Patients With Heart Failure Due to Reduced or Preserved Ejection Fraction: The MIRACLE-AF 2 Heart Failure Management Trial (MIRACLE AF-HF) NCT07492524 · Recruiting · Phase NA · started 2026-07-26
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 NCT06716021 · Recruiting · Phase PHASE3 · started 2026-08-20
- A Village Doctor-led Telehealth Supported Trial of Heart Failure Prevention in AF Patients: MIRACLE-AF 2 (Heart Failure Prevention) NCT07492498 · Recruiting · Phase NA · started 2026-07-26
- BoxX-NoAF Clinical Trial NCT06989775 · Recruiting · Phase NA · started 2025-10-24
- PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort NCT02485288 · Active Not Recruiting · started 2015-06
- Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation NCT04625946 · Completed · Phase PHASE4 · started 2021-01-19
- A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation NCT07625215 · Recruiting · Phase PHASE2 · started 2026-09-01
- Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation NCT05462145 · Active Not Recruiting · Phase NA · started 2023-03-09
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.